Zoetis Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Zoetis de 8.6% y 6% por año respectivamente. Se prevé que el BPA crezca en un 9% al año. Se espera que la rentabilidad financiera sea de 42.9% en 3 años.

Información clave

8.6%

Tasa de crecimiento de los beneficios

9.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	27.6%
Tasa de crecimiento de los ingresos	6.0%
Rentabilidad financiera futura	42.9%
Cobertura de analistas	Good
Última actualización	12 Jun 2024

Actualizaciones recientes sobre el crecimiento futuro

The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 04

Recent updates

The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 04

Zoetis: Long-Term Buy Despite Safety Concerns

May 03

Despite Lawsuit Risks: Why Zoetis Remains A Compelling Investment

Apr 15

Zoetis Inc.'s (NYSE:ZTS) Shareholders Might Be Looking For Exit

Apr 12

Zoetis: My Favorite Healthcare Stock Right Now

Mar 21

Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)

Mar 03

Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness

Feb 27

Animal Kingdom's Ally: Zoetis And Its Path To 10%+ Returns

Jan 10

Some Confidence Is Lacking In Zoetis Inc.'s (NYSE:ZTS) P/E

Jan 01

Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's

Dec 14

Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?

Dec 06

Here's Why We Think Zoetis (NYSE:ZTS) Might Deserve Your Attention Today

Nov 18

Zoetis: High-Quality Compounder With A Reasonable Price After Earnings

Nov 09

Zoetis: Significant CapEx Investments For Long-Term Growth, But A Hold Now

Oct 26

Zoetis Is An Impressive Healthcare Compounder

Sep 26

Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Sep 25

Here's Why Zoetis (NYSE:ZTS) Can Manage Its Debt Responsibly

Sep 04

Zoetis: Pawses Pain, Librela OA Treatment Targets Furry Friends In The U.S.

Aug 22

Should You Be Adding Zoetis (NYSE:ZTS) To Your Watchlist Today?

Aug 12

Zoetis: My Dog Approves Of This Dividend Compounder

Jul 19

Zoetis: A Purrfect Addition To Your Portfolio

Jun 22

Does This Valuation Of Zoetis Inc. (NYSE:ZTS) Imply Investors Are Overpaying?

Jun 10

These 4 Measures Indicate That Zoetis (NYSE:ZTS) Is Using Debt Reasonably Well

Apr 16

Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Mar 10

Zoetis rises on 2023 revenue forecast above estimates, Q4 profit in-line with consensus

Feb 14

Zoetis Is An Awesome Dividend Growth Stock

Jan 17

It's A Great Time To Buy Zoetis Shares

Jan 10

Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's

Jan 03

Is Zoetis (NYSE:ZTS) Using Too Much Debt?

Dec 29

Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's

Dec 14

Zoetis raises quarterly dividend by 15.4% to $0.375/share

Dec 08

Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)

Nov 20

Zoetis' Q3 Earnings: Supply Issues Putting A Dent On Growth

Nov 08

Zoetis Q3 2022 Earnings Preview

Nov 02

Does Zoetis (NYSE:ZTS) Deserve A Spot On Your Watchlist?

Nov 02

Zoetis declares $0.325 dividend

Oct 13

A Rising Dollar May Mean Lower Zoetis Shares

Oct 07

Is Zoetis (NYSE:ZTS) Using Too Much Debt?

Sep 15

Zoetis cleared to acquire Jurox in Australia subject to divestiture

Sep 15

Previsiones de crecimiento de beneficios e ingresos

NYSE:ZTS - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	10,372	3,005	2,699	3,384	13
12/31/2025	9,759	2,760	2,444	3,188	15
12/31/2024	9,150	2,489	2,203	2,930	15
3/31/2024	8,734	2,391	1,750	2,399	N/A
12/31/2023	8,544	2,344	1,621	2,353	N/A
9/30/2023	8,371	2,280	1,492	2,197	N/A
6/30/2023	8,222	2,213	1,285	1,999	N/A
3/31/2023	8,094	2,071	1,458	2,152	N/A
12/31/2022	8,080	2,114	1,326	1,912	N/A
9/30/2022	8,007	2,067	1,267	1,850	N/A
6/30/2022	7,995	2,090	1,429	1,977	N/A
3/31/2022	7,891	2,073	1,607	2,122	N/A
12/31/2021	7,776	2,037	1,736	2,213	N/A
9/30/2021	7,616	1,982	1,791	2,252	N/A
6/30/2021	7,412	1,909	1,702	2,161	N/A
3/31/2021	7,012	1,774	1,682	2,118	N/A
12/31/2020	6,675	1,638	1,673	2,126	N/A
9/30/2020	6,542	1,663	1,523	1,990	N/A
6/30/2020	6,340	1,617	1,456	1,934	N/A
3/31/2020	6,339	1,611	1,323	1,814	N/A
12/31/2019	6,260	1,500	1,335	1,795	N/A
9/30/2019	6,150	1,461	1,365	1,797	N/A
6/30/2019	6,046	1,375	1,463	1,841	N/A
3/31/2019	5,914	1,388	1,442	1,790	N/A
12/31/2018	5,825	1,428	1,452	1,790	N/A
9/30/2018	5,721	1,164	1,531	1,814	N/A
6/30/2018	5,588	1,115	1,446	1,703	N/A
3/31/2018	5,442	978	1,381	1,616	N/A
12/31/2017	5,307	864	N/A	1,346	N/A
10/1/2017	5,124	937	N/A	1,024	N/A
7/2/2017	5,018	878	N/A	824	N/A
4/2/2017	4,957	855	N/A	781	N/A
12/31/2016	4,888	821	N/A	713	N/A
10/2/2016	4,885	689	N/A	705	N/A
7/3/2016	4,858	639	N/A	670	N/A
4/3/2016	4,825	378	N/A	655	N/A
12/31/2015	4,765	339	N/A	664	N/A
9/27/2015	4,811	443	N/A	773	N/A
6/28/2015	4,807	420	N/A	672	N/A
3/29/2015	4,790	593	N/A	709	N/A
12/31/2014	4,785	583	N/A	626	N/A
9/28/2014	4,719	562	N/A	537	N/A
6/29/2014	4,612	527	N/A	548	N/A
3/30/2014	4,568	519	N/A	377	N/A
12/31/2013	4,561	504	N/A	681	N/A
9/29/2013	4,483	389	N/A	693	N/A
6/30/2013	4,399	420	N/A	653	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (8.6% al año) de ZTS es superior a la tasa de ahorro (2.4%).

Beneficios vs. Mercado: Se prevé que los beneficios (8.6% al año) de ZTS crezcan menos que el mercado US (14.8% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de ZTS crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (6% al año) de ZTS crezcan más despacio que el mercado de US (8.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 6% al año) de ZTS crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de ZTS sea muy elevada dentro de 3 años (42.9%).

Zoetis Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Zoetis Inc. Revises Earnings Guidance for the Year 2024

Zoetis Inc. Provides Earnings Guidance for the Full Year 2023

Zoetis Inc. Maintains Earnings Guidance for the Full Year 2023

Zoetis Inc. Provides Earning Guidance for Full Year 2023

Zoetis Inc. Provides Earnings Guidance for the Full Year 2022

Recent updates

Zoetis: Don't Fret Excessively Over The Animal Healthcare Leader

A Look At The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

First quarter dividend of US$0.43 announced

Zoetis Inc. Announces Retirement of Linda Rhodes as Board of Directors

Zoetis (NYSE:ZTS) Ticks All The Boxes When It Comes To Earnings Growth

Zoetis Inc. Declares Dividend for the Third Quarter of 2024, Payable on September 4, 2024

Zoetis: Why The Focus On Companion Animal Segment Will Pay Off

Employee Advisor notifies of intention to sell stock

The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Zoetis: Long-Term Buy Despite Safety Concerns

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Zoetis Inc. Revises Earnings Guidance for the Year 2024

Phibro Animal Health Corporation (NasdaqGM:PAHC) entered into a definitive agreement to acquire Medicated feed additive product portfolio, certain water soluble products and related assets of Zoetis Inc. (NYSE:ZTS) for approximately $350 million.

Zoetis Inc. Announces Executive Changes

Despite Lawsuit Risks: Why Zoetis Remains A Compelling Investment

Now 22% undervalued after recent price drop

Zoetis Inc.'s (NYSE:ZTS) Shareholders Might Be Looking For Exit

Zoetis Inc., Annual General Meeting, May 22, 2024

Upcoming dividend of US$0.43 per share

Zoetis Inc. Appoints Gavin D.K. Hattersley to Its Board of Directors

Zoetis: My Favorite Healthcare Stock Right Now

Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)

Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness

CEO & Director notifies of intention to sell stock

CEO & Director exercised options and sold US$3.6m worth of stock

Full year 2023 earnings: EPS misses analyst expectations

Dividend of US$0.43 announced

Zoetis Inc. Declares Second Quarter 2024 Dividend, Payable on June 4, 2024

Upcoming dividend of US$0.43 per share at 0.9% yield

Animal Kingdom's Ally: Zoetis And Its Path To 10%+ Returns

Some Confidence Is Lacking In Zoetis Inc.'s (NYSE:ZTS) P/E

Insufficient new directors

Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's

Zoetis Inc. Declares Dividend for the First Quarter of 2024, Payable on March 1, 2024

Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?

CEO & Director exercised options and sold US$1.7m worth of stock

Here's Why We Think Zoetis (NYSE:ZTS) Might Deserve Your Attention Today

Zoetis: High-Quality Compounder With A Reasonable Price After Earnings

Zoetis Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Zoetis: Significant CapEx Investments For Long-Term Growth, But A Hold Now

Upcoming dividend of US$0.38 per share at 0.9% yield

Zoetis Inc. Declares Dividend for the Fourth Quarter of 2023, Payable on December 1, 2023

Zoetis Is An Impressive Healthcare Compounder

Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

Executive VP notifies of intention to sell stock

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH from founders, High-Tech Gründerfonds, the Swiss Occident Group AG and MorphoSys AG (XTRA:MOR).

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH.

Here's Why Zoetis (NYSE:ZTS) Can Manage Its Debt Responsibly

CEO & Director exercised options and sold US$1.7m worth of stock

Zoetis: Pawses Pain, Librela OA Treatment Targets Furry Friends In The U.S.

Should You Be Adding Zoetis (NYSE:ZTS) To Your Watchlist Today?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Zoetis: My Dog Approves Of This Dividend Compounder

Upcoming dividend of US$0.38 per share at 0.9% yield

Zoetis Inc. Announces Appointment of Ester Banque as Executive Vice President and President, U.S. Operations

Zoetis: A Purrfect Addition To Your Portfolio

Does This Valuation Of Zoetis Inc. (NYSE:ZTS) Imply Investors Are Overpaying?

CEO & Director notifies of intention to sell stock

JAB Holdings B.V. acquired an unknown majority interest in Pumpkin Insurance Services Inc. from Zoetis Inc. (NYSE:ZTS).

Zoetis Inc. Declares Dividend for Third Quarter of 2023, Payable on September 1, 2023

Zoetis Inc. Announces U.S. Food and Drug Administration Approves Librela™ (Bedinvetmab Injection) for Control of Pain Associated with Osteoarthritis in Dogs

Zoetis Inc. Maintains Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: Revenues and EPS in line with analyst expectations

Key Executive exercised options and sold US$417k worth of stock

These 4 Measures Indicate That Zoetis (NYSE:ZTS) Is Using Debt Reasonably Well

Upcoming dividend of US$0.38 per share at 0.9% yield

Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)

CEO & Director exercised options and sold US$2.0m worth of stock